Recombinant rotavirus (trivalent) vaccine is under clinical development by MAXVAX Biotechnology and currently in Phase II for Rotavirus Infections. According to GlobalData, Phase II drugs for Rotavirus Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Recombinant rotavirus (trivalent) vaccine LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Recombinant rotavirus (trivalent) vaccine overview

The vaccine candidate is under development for the prevention of rotavirus infections. It is a trivalent recombinant vaccine and is administered through parenteral route.

MAXVAX Biotechnology overview

MAXVAX Biotechnology (Maxvax) is a developer of biological vaccine that mainly engaged in the research and development, production, promotion and sales of new influenza vaccines, new rabies vaccines, new rotavirus vaccines and new senile herpes zoster vaccines. Maxvax is headquartered in Chengdu, Sichuan, China.

For a complete picture of Recombinant rotavirus (trivalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.